WASHINGTON, March 7, 2022 /PRNewswire/ — EverGlade Consulting (“EverGlade”), a Washington, D.C. based consulting firm, has successfully aided Detect, Inc. (“Detect”) in securing a contract with BARDA for the advanced development of a next generation diagnostic device […] an over-the-counter home test that identifies and distinguishes between SARS-CoV-2 and influenza A and B nucleic acid using a single nasal swab.
EverGlade Consulting Assists Detect, Inc. with Securing $22m in Federal Funding for the Development of a Next Generation Molecular Test for COVID-19 and Flu
